Home Other Building Blocks Lomerizine hydrochloride

Lomerizine hydrochloride

CAS No.:
101477-54-7
Catalog Number:
AG0004KV
Molecular Formula:
C27H32Cl2F2N2O3
Molecular Weight:
541.4574
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
50mg
99%
1 week
United States
$154
- +
200mg
>98.0%(T)(HPLC)
1 week
United States
$180
- +
Product Description
Catalog Number:
AG0004KV
Chemical Name:
Lomerizine hydrochloride
CAS Number:
101477-54-7
Molecular Formula:
C27H32Cl2F2N2O3
Molecular Weight:
541.4574
MDL Number:
MFCD01703867
IUPAC Name:
1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine;dihydrochloride
InChI:
InChI=1S/C27H30F2N2O3.2ClH/c1-32-24-13-8-21(26(33-2)27(24)34-3)18-30-14-16-31(17-15-30)25(19-4-9-22(28)10-5-19)20-6-11-23(29)12-7-20;;/h4-13,25H,14-18H2,1-3H3;2*1H
InChI Key:
LOGVKVSFYBBUAJ-UHFFFAOYSA-N
SMILES:
COc1c(ccc(c1OC)OC)CN1CCN(CC1)C(c1ccc(cc1)F)c1ccc(cc1)F.Cl.Cl
UNII:
3W473D5LIY
Properties
Complexity:
568  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
3  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
540.176g/mol
Formal Charge:
0
Heavy Atom Count:
36  
Hydrogen Bond Acceptor Count:
7  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
541.461g/mol
Monoisotopic Mass:
540.176g/mol
Rotatable Bond Count:
8  
Topological Polar Surface Area:
34.2A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
Title Journal
Why are most phospholipidosis inducers also hERG blockers? Archives of toxicology 20171201
Changes in optic nerve head circulation in response to vasoactive agents: intereye comparison in monkeys with experimental unilateral glaucoma. Investigative ophthalmology & visual science 20120822
Neuroprotection by lomerizine, a prophylactic drug for migraine, against hydrogen peroxide-induced hippocampal neurotoxicity. Molecular and cellular biochemistry 20111201
Development of spontaneous neuropathy in NF-κBp50-deficient mice by calcineurin-signal involving impaired NF-κB activation. Molecular vision 20110101
Interaction of CJZ3, a lomerizine derivative, with ATPase activity of human P-glycoprotein in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Die Pharmazie 20100701
Lomerizine, a Ca2+ channel blocker, protects against neuronal degeneration within the visual center of the brain after retinal damage in mice. CNS neuroscience & therapeutics 20100401
Limited restoration of visual function after partial optic nerve injury; a time course study using the calcium channel blocker lomerizine. Brain research bulletin 20100316
A case of ocular hypertension complicated by SUNCT syndrome. Annals of ophthalmology (Skokie, Ill.) 20100101
Secondary retinal ganglion cell death and the neuroprotective effects of the calcium channel blocker lomerizine. Investigative ophthalmology & visual science 20091101
Inhibitory effect of lomerizine, a prophylactic drug for migraines, on serotonin-induced contraction of the basilar artery. Journal of pharmacological sciences 20091001
[Calcium antagonists in the prophylactic treatment of migraine]. Brain and nerve = Shinkei kenkyu no shinpo 20091001
Secondary degeneration of the optic nerve following partial transection: the benefits of lomerizine. Experimental neurology 20090301
Cognitive impairment and cerebral hypoperfusion in a CADASIL patient improved during administration of lomerizine. Clinical neuropharmacology 20090101
[CADASIL]. Brain and nerve = Shinkei kenkyu no shinpo 20081101
Goshuyuto, a traditional Japanese medicine for migraine, inhibits platelet aggregation in guinea-pig whole blood. Journal of pharmacological sciences 20080901
Atypical depression as a premonitory symptom of migraine managed by an oral contraceptive. Psychiatry and clinical neurosciences 20080601
Migraine-associated vertigo: clinical characteristics of Japanese patients and effect of lomerizine, a calcium channel antagonist. Acta oto-laryngologica. Supplementum 20071201
CJZ3, a lomerizine derivative, modulates P-glycoprotein function in rat brain microvessel endothelial cells. Acta pharmacologica Sinica 20060401
A new calcium channel antagonist, lomerizine, alleviates secondary retinal ganglion cell death after optic nerve injury in the rat. Current eye research 20060301
[Reversal of multidrug resistance by lomerizine in K562/ADM cells]. Yao xue xue bao = Acta pharmaceutica Sinica 20040501
Clinical potential of lomerizine, a Ca2+ channel blocker as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovascular drug reviews 20040101
[Effects of changes in conformation and configuration of N-containing compounds on NMR spactra]. Yao xue xue bao = Acta pharmaceutica Sinica 20031201
Effects of lomerizine, a calcium channel antagonist, on retinal and optic nerve head circulation in rabbits and humans. Investigative ophthalmology & visual science 20031101
Increase in doxorubicin cytotoxicity by inhibition of P-glycoprotein activity with lomerizine. Biological & pharmaceutical bulletin 20010501
Effects of lomerizine, a novel Ca2+ channel blocker, on the normal and endothelin-1-disturbed circulation in the optic nerve head of rabbits. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20010401
Properties